Monday, March 9, 2015

5 biggest Health Care Equipment & Services average 8% YTD Gain

  • The five largest capitalised Health Care Equipment & Services stocks listed on SGX are IHH Healthcare Bhd, Raffles Medical Group, Biosensors International Group, Religare Health Trust, and TalkMed Group.
  • These five stocks have averaged a 7.6% price gain in the year-to-date and maintain an average dividend yield of 2.9%.
  • Three of these stocks have been listed in recent years – IHH Healthcare Bhd and Religare Health Trust in 2012, and TalkMed Group in 2014. These three stocks have averaged a 43% gain from their first day close.
Modern day health care stocks span a wide range of health-related businesses – from the traditional plays of hospitals and clinics to medical supplies and hit-tech medical equipment to pharmaceuticals including western and traditional Chinese medicines.

Singapore Exchange (SGX) lists almost 30 stocks that represent the Healthcare sector. Among the group are 19 Health Care Equipment & Services stocks as categorised by the Global Industry Classification Standard (GICS®) with a  combined market capitalisation of S$23.8 billion. The five largest capitalised stocks in this group of 19 stocks have averaged a price gain of 7.6% in the year thus far and maintain a dividend yield of 2.9%. These five stocks are IHH Healthcare Berhad, Raffles Medical Group, Biosensors International Group, Religare Health Trust, and TalkMed Group. Three of these stocks have been listed in recent years – IHH Healthcare Bhd and Religare Health Trust in 2012, and TalkMed Group in 2014. As detailed in the table below, these three stocks have averaged a 43.3% gain from their first day close.

Source: SGX StockFacts & S&P Capital IQ (Data as of 3 March 2015)

The table below details the 19 Health Care Equipment & Services stocks sorted according to market capitalisation. Please also note that clicking directly on the stock name below will take you to the relevant profile page on SGX StockFacts.
Source: SGX StockFacts & S&P Capital IQ (Data as of 3 March 2015)

As noted above, the five largest capitalised stocks averaged 7.6% price gain in the year-to-date. The businesses of  these five stocks are as follows:

IHH Healthcare Berhad
IHH Healthcare Berhad provides healthcare services primarily in Asia, Central and Eastern Europe, the Middle East, and North Africa. It provides primary care services, including treatment of basic illnesses, routine check-ups, vaccination, and dental services. The company also offers secondary and tertiary care services in addition to providing a range of ancillary services. The company was formerly known as Integrated Healthcare Holdings Berhad and changed its name to IHH Healthcare Berhad in April 2012. IHH Healthcare Berhad is based in Kuala Lumpur, Malaysia.

IHH Healthcare Berhad has a market capitalisation of S$16.9 billion. On 26 February 2015, the company reported that their revenue for the quarter ended 31 December 2014, increased by 8.8% year on year to MYR1.9 billion (click here to view more). On the same day, the company also announced that it had undertaken a revaluation exercise to ascertain the current market value of the Investment Properties (clickhere to view more).
The five biggest substantial shareholders of IHH Healthcare Berhad are Khazanah Nasional Berhad, Mitsui & Co. Ltd., Employees Provident Fund of Malaysia, Permodalan Nasional Berhad and Aydinlar, Mehmet Ali.

Raffles Medical Group
Raffles Medical Group provides a range of medical services in Singapore. It owns and operates a network of family medicine clinics and a tertiary care private hospital. The company’s flagship hospital is Raffles Hospital, a private tertiary hospital offering various specialist medical and diagnostic services for inpatients and outpatients in Singapore with representative offices in Indonesia, Vietnam, Cambodia, Brunei, Bangladesh, and the Russian Far East. It also provides health insurance policies for corporate and individual clients. Raffles Medical Group Ltd was founded in 1976 and is based in Singapore.

Raffles Medical Group Ltd has a market capitalisation of S$2.2 billion and the stock trades at a P/E ratio of 32.9. Shares in the stock went ex-dividend on 18 August 2014, distributing S$0.015 per share.
On 16 February 2015, the company announced that their revenue for the year ended 31 December 2014, increased by 9.9% year on year to S$374.6 million (click here to view more). On 1 December 2014, the company also announced that they will be building a new extension building for Raffles Hospital to meet the demands of local and foreign patients. The extension building will be 20-storey high with two basements and will cost S$310 million. The completion of this building will double their existing hospital facilities size (clickhere to view more).
The five biggest substantial shareholders of Raffles Medical Group are Raffles Medical Holdings Pte. Ltd., Loo, Choon Yong, Aberdeen Asset Management PLC, BNP Paribas, Private & Investment Banking Investments and FIL Limited.

Biosensors International Group
Biosensors International Group, Ltd., an investment holding company, develops, manufactures, and markets various medical devices for interventional cardiology and critical care procedures in China, Japan, and internationally. The company operates in four segments: Interventional Cardiology, Critical Care, Cardiac Diagnostic, and Licensing Revenue. The company was founded in 1990 and is headquartered in Singapore.
Biosensors International Group, Ltd. has a market capitalisation of S$1.1 billion and the stock trades at a P/E ratio of 30.0.

On 12 February 2015, the company reported that their revenue for the nine months ended 31 December 2014, increased by 1.0% year on year to US$211.0 million (click here to view more). On 9 February 2015, the company also announced the completion of the patient enrolment in LEADERS Free Japan, a revolutionary trial involving BioFreedom™, the company’s novel polymer and carrier-free drug coated stent (DCS) (clickhere to view more).
The five biggest substantial shareholders of Biosensors International Group Ltd. are Shandong Weigao Group Medical Polymer Co., Limited, Hony Capital (Beijing) Co., Ltd., CIMB Group Holdings Berhad, Asset Management Arm, Norges Bank Investment Management and FIL Limited.

Religare Health Trust
Religare Health Trust, a business trust, provides medical and clinical establishment services in India. It has a portfolio of 11 clinical establishments, 4 greenfield clinical establishments, and 2 operating hospitals. The company was founded in 2011 and is based in Singapore.

Religare Health Trust has a market capitalisation of S$858.2 million and the stock trades at a P/E ratio of 22.4. Shares in the stock went ex-dividend on 20 November 2014, distributing S$0.0361 per share.
On 13 February 2015, the company announced that their total revenue for the quarter ended 31 December 2014, increased by 26.9% to S$34.1 million year on year (click here to view more). The company attributed the increase of revenue to the increase in service fee as a result of additional contribution from the newly added Mohali clinical establishment and increase in base fee and the contribution from variable fee from Gurgaon clinical establishment post the stabilisation period which ended on 31 March 2014.
The five biggest substantial shareholders of Religare Health Trust are Fortis Global Healthcare Infrastructure Pte Ltd., FIL Limited, Swordfish Investments Pte. Ltd, Seatown Swordfish Pte Ltd and Polar Capital Holdings PLC.

TalkMed Group
TalkMed Group provides medical oncology services to the oncology patients under the Parkway Cancer Centre brand name. It also provides palliative care services; and ancillary health services, such as CANSCREEN, a screening program that provides screening for individuals at a risk of getting cancer. The company operates a network of seven clinics in Singapore. TalkMed Group Limited was incorporated in 2013 and is based in Singapore.

TalkMed has a market capitalisation of S$693.3 million and the stock trades at a P/E ratio of 17.8. Shares in the stock will go ex-dividend on 4 May 2015, distributing S$0.0243 per share.
On 25 February 2015, the company announced that their revenue for the quarter ended 31 December 2014, increased by 16.3% to S$17.3 million (click here to view more). The company also announced on 26 January 2015 that the company had entered into a shareholders’ agreement with StemCord Pte. Ltd. to incorporate Stem Med Pte. Ltd. with a registered capital of S$3,000,000. The principal activity of Stem Med is for the provision of medical services related to cellular therapy (click here to view more).
The five biggest substantial shareholders of TalkMed Group are Ladyhill Holdings Pte. Ltd., Khoo, Kei Siong, Teo, Cheng Peng, Lim, Hong Liang and QAP Capital Pte Ltd.

Source: My Gateway

Related Posts Plugin for WordPress, Blogger...